Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells

Mediators of PI3K/AKT signaling have been implicated in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Studies have shown that inhibitors of PI3K/AKT signaling, such as wortmannin and LY294002, are able to inhibit CML and AML cell proliferation and synergize with targeted tyrosine...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Weisberg, Ellen, Banerji, Lolita, Wright, Renee D., Barrett, Rosemary, Ray, Arghya, Moreno, Daisy, Catley, Laurence, Jiang, Jingrui, Hall-Meyers, Elizabeth, Sauveur-Michel, Maira, Stone, Richard, Galinsky, Ilene, Fox, Edward, Kung, Andrew L., Griffin, James D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2008
Gaiak:
Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2275029/
https://ncbi.nlm.nih.gov/pubmed/18184863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-09-114454
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak